(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of -1.14% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Becton Dickinson & Co's revenue in 2026 is $21,366,000,000.On average, 18 Wall Street analysts forecast BDX's revenue for 2026 to be $5,348,239,688,070, with the lowest BDX revenue forecast at $5,164,178,682,834, and the highest BDX revenue forecast at $5,590,715,263,830. On average, 18 Wall Street analysts forecast BDX's revenue for 2027 to be $5,491,796,250,537, with the lowest BDX revenue forecast at $5,277,425,798,331, and the highest BDX revenue forecast at $5,850,274,346,064.
In 2028, BDX is forecast to generate $5,701,206,975,057 in revenue, with the lowest revenue forecast at $5,384,059,943,580 and the highest revenue forecast at $6,147,306,926,370.